Home › Macular Degeneration › NCT06346600

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Who can join

Ages 50 and older · All sexes

Inclusion Criteria:

Subjects who only meet all of the following criteria are eligible for this study:

* nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
* Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study

Exclusion Criteria:

* Subjects who are judged by the investigator unsuitable for this study

About the study

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.

What is being tested

• SKG0106 (genetic)

Sponsor: Skyline Therapeutics · Participants: 83 · Started: Apr 2, 2025

Contact the study team

• Eddy Anglade, MD · Phone: +1-908-884-1246

Official record on ClinicalTrials.gov — NCT06346600

Locations in the U.S.

Conditions

• Macular Degeneration

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.